A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Clinical trial NCT05941897 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT05941897

Sponsor

AstraZeneca

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2023-06-21

Primary completion

2024-07-29

Enrollment

39

View on ClinicalTrials.gov